At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Pre-Mkt 03-23 06:01:58 EDT
0.7622
-0.0013
-0.17%
High0.7900Low0.7210Vol89.90K
Open0.7635D1 Closing0.7635Amplitude9.04%
Mkt Cap8.73MTradable Cap7.38MTotal Shares11.45M
T/O68.20KT/O Rate0.93%Tradable Shares9.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
TIPRANKS  ·  03-17
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
THOMSON REUTERS  ·  03-16
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
TIPRANKS  ·  02-20
Aprea Therapeutics files to sell 12.58M shares of common stock for holders
BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051
Reuters  ·  02-18
BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051
Aprea Therapeutics announces additional clinical activity for APR-1051
TIPRANKS  ·  02-18
Aprea Therapeutics announces additional clinical activity for APR-1051
Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial
Reuters  ·  02-18
Aprea Therapeutics reports second partial response in APR-1051 ACESOT-1051 trial
Aprea Therapeutics Inc - Update From Trial Is Expected in Q2 of 2026
THOMSON REUTERS  ·  02-18
Aprea Therapeutics Inc - Update From Trial Is Expected in Q2 of 2026
Aprea Therapeutics Inc - Tumor Shrinkage of 50% and Significant CA-125 Biomarker Reduction Observed at 220 Mg Dose Level
THOMSON REUTERS  ·  02-18
Aprea Therapeutics Inc - Tumor Shrinkage of 50% and Significant CA-125 Biomarker Reduction Observed at 220 Mg Dose Level
Aprea Therapeutics Announces Additional Positive Clinical Activity for Wee1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing Acesot-1051 Trial
THOMSON REUTERS  ·  02-18
Aprea Therapeutics Announces Additional Positive Clinical Activity for Wee1 Inhibitor, Apr-1051, Including Second Partial Response in Ongoing Acesot-1051 Trial
BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
Reuters  ·  02-12
BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
Aprea Therapeutics Inc - Existing Issued Patents Expected to Remain in Force Through 2035-2037
THOMSON REUTERS  ·  02-12
Aprea Therapeutics Inc - Existing Issued Patents Expected to Remain in Force Through 2035-2037
Aprea Therapeutics Inc - Granted New Patents in Australia and Japan
THOMSON REUTERS  ·  02-12
Aprea Therapeutics Inc - Granted New Patents in Australia and Japan
Aprea Therapeutics Inc - Core Patent Families Expected to Provide Exclusivity Into 2045
THOMSON REUTERS  ·  02-12
Aprea Therapeutics Inc - Core Patent Families Expected to Provide Exclusivity Into 2045
Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio
Reuters  ·  02-12
Aprea Therapeutics Secures New Patents in Australia and Japan to Strengthen Global DDR Cancer Therapy Portfolio
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (Ddr) Cancer Therapeutics, Paving Way for Pipeline Growth
THOMSON REUTERS  ·  02-12
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (Ddr) Cancer Therapeutics, Paving Way for Pipeline Growth
Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor
Reuters  ·  02-04
Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor
Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares
Reuters  ·  02-03
Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
Reuters  ·  02-03
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM
Reuters  ·  01-31
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM
Aprea Therapeutics prices 6.29M shares at 89c in private placement
TIPRANKS  ·  01-29
Aprea Therapeutics prices 6.29M shares at 89c in private placement

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--